胰高血糖素样肽-1受体激动剂能减缓常染色体显性多囊肾病的进展吗？
Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?
作者信息
Ali Hamad, Alahmad Barrak, Al-Mulla Fahd
机构信息
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Department of Translational Medicine, Dasman Diabetes Institute (DDI), Dasman, Kuwait.
出版信息
BMC Nephrol. 2025 Jun 4;26(1):279. doi: 10.1186/s12882-025-04217-w.
Abstract
GLP-1 receptor agonists revolutionized diabetes therapy and offer cardiorenal protection in diabetic kidney disease. Their potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD) is now being explored. Preclinical findings and metabolic improvements (obesity, hypertension, inflammation) indicate promise. Further clinical studies are required to ensure efficacy and safety before clinical integration can be considered. Clinical trial number: Not applicable.
摘要
胰高血糖素样肽-1（GLP-1）受体激动剂彻底改变了糖尿病治疗方式，并为糖尿病肾病提供心脏肾脏保护作用。目前正在探索其在常染色体显性多囊肾病（ADPKD）中的潜力。临床前研究结果及代谢改善情况（肥胖、高血压、炎症）显示出应用前景。在考虑临床应用之前，还需要进一步的临床研究以确保其疗效和安全性。临床试验编号：不适用。
相似文献
1
Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?胰高血糖素样肽-1受体激动剂能减缓常染色体显性多囊肾病的进展吗？
BMC Nephrol. 2025 Jun 4;26(1):279. doi: 10.1186/s12882-025-04217-w.
2
The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant Polycystic Kidney Disease.非药物和药物干预对常染色体显性遗传性多囊肾病病程的影响。
Nutrients. 2024 Sep 23;16(18):3216. doi: 10.3390/nu16183216.
3
The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.辅助药物在改善1型糖尿病治疗效果方面的前景：胰高血糖素样肽受体激动剂
J Diabetes Sci Technol. 2025 Mar;19(2):311-320. doi: 10.1177/19322968241309896. Epub 2024 Dec 31.
4
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?二甲双胍在常染色体显性多囊肾病中的应用：实验假说还是临床事实？
BMC Nephrol. 2018 Oct 22;19(1):282. doi: 10.1186/s12882-018-1090-3.
5
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.胰高血糖素样肽-1激动剂在延缓慢性肾脏病进展方面的新证据。
Curr Opin Nephrol Hypertens. 2024 May 1;33(3):331-336. doi: 10.1097/MNH.0000000000000976. Epub 2024 Feb 23.
6
Glucagon-like peptide-1 receptor agonists and kidney outcomes.胰高血糖素样肽-1 受体激动剂与肾脏结局。
J Diabetes. 2024 Oct;16(10):e13609. doi: 10.1111/1753-0407.13609.
7
Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传性多囊肾病的靶向治疗。
Curr Med Chem. 2019;26(17):3081-3102. doi: 10.2174/0929867325666180508095654.
8
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.TEMPO（托伐普坦治疗常染色体显性遗传多囊肾病及其结局的疗效和安全性）3-4 研究的原理和设计。
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
9
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.糖尿病肾病中的SGLT2抑制剂和GLP-1受体激动剂：不断发展的证据与临床应用
Diabetes Metab J. 2025 May;49(3):386-402. doi: 10.4093/dmj.2025.0220. Epub 2025 May 1.
10
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.接受胰高血糖素样肽-1受体激动剂的慢性肾脏病患者的肾脏和心血管结局：一项随机试验的系统评价和荟萃分析
Am J Kidney Dis. 2025 May;85(5):555-569.e1. doi: 10.1053/j.ajkd.2024.11.013. Epub 2025 Jan 23.
本文引用的文献
1
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.常染色体显性多囊肾病：近期遗传学和临床进展概述
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
2
Autosomal Dominant Polycystic Kidney Disease: A Review.常染色体显性多囊肾病：综述
JAMA. 2025 May 20;333(19):1708-1719. doi: 10.1001/jama.2025.0310.
3
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者的超重状态、肥胖与终末期肾病进展
Clin J Am Soc Nephrol. 2025 Apr 1;20(4):520-528. doi: 10.2215/CJN.0000000640. Epub 2025 Feb 19.
4
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.胰高血糖素样肽-1受体激动剂对肾脏结局的影响：一项随机安慰剂对照试验的荟萃分析
Clin J Am Soc Nephrol. 2024 Oct 8;20(2):159-68. doi: 10.2215/CJN.0000000584.
5
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
6
Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.内脏脂肪与常染色体显性多囊肾病的进展：来自TEMPO 3:4试验患者的队列研究
Am J Kidney Dis. 2024 Sep;84(3):275-285.e1. doi: 10.1053/j.ajkd.2024.02.014. Epub 2024 Apr 10.
7
Cardiovascular Manifestations and Management in ADPKD.常染色体显性多囊肾病的心血管表现与管理
Kidney Int Rep. 2023 Aug 4;8(10):1924-1940. doi: 10.1016/j.ekir.2023.07.017. eCollection 2023 Oct.
8
The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.GLP-1 受体激动剂对伴有或不伴有糖尿病和非酒精性脂肪性肝病的成年人群内脏脂肪和肝脏异位脂肪的影响：系统评价和荟萃分析。
PLoS One. 2023 Aug 24;18(8):e0289616. doi: 10.1371/journal.pone.0289616. eCollection 2023.
9
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.胰高血糖素样肽-1受体激动剂在糖尿病肾病中的应用：肾脏与心脏保护作用综述
Am J Prev Cardiol. 2023 May 24;14:100502. doi: 10.1016/j.ajpc.2023.100502. eCollection 2023 Jun.
10
The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms.胰高血糖素样肽-1受体激动剂的降压作用：潜在机制的小型综述
Curr Opin Pharmacol. 2023 Apr;69:102355. doi: 10.1016/j.coph.2023.102355. Epub 2023 Feb 28.
Zotero 插件